← Back to all trials
Active Not Recruiting
NCT03508752
Neurocognitive Decline in Patients With Brain Metastases
Conditions: Brain Metastases
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE1, PHASE2
Enrollment: 80
Sponsor: University of Texas Southwestern Medical Center
Location: University of Texas Southwestern Medical Center Dallas Texas
Summary
The phase I component of the study is to identify maximal tolerated dose (MTD). The phase II is to evaluate neurocognitive decline.
Eligibility Criteria
Inclusion Criteria:
1. Age ≥ 18 years.
2. ECOG Performance Score of 2 or better/Karnofsky Performance score of 50-60 or better.
3. Biopsy-proven non-hematopoietic malignancy, except for germ cell cancer. Small cell lung carcinoma is eligible for this study.
4. Six or more metastases on diagnostic or treatment planning imaging, which include either CT Brain (with contrast) or MR Brain (with or without contrast) imaging.
5. Largest tumor \
Source: ClinicalTrials.gov (NCT03508752). StuddyBuddy aggregates publicly available trial information.
